ArticleLupus science & medicine2025
HDAC3 knockdown inhibits ferroptosis via upregulating Nrf2 to alleviate renal interstitial fibrosis in lupus nephritis.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLupus nephritis (LN) is the most serious complication of SLE. Interstitial fibrosis is the dominant pathological change of renal injury in LN. Enhanced histone deacetylase 3 (HDAC3) positively correlates with renal interstitial fibrosis (RIF). Our study objective was to explore the accurate role and mechanism of HDAC3 in the RIF of LN.
methodsTo knock down HDAC3, Murphy Roths large (MRL)/wt and MRL/MpJ-Faslpr/J (MRL/lpr mice were injected with lentiviral short hairpin RNAs. Human renal proximal tubular epithelial cells (HK-2 cells) were treated with serum from patients with LN to establish an LN cell model. Renal histopathological change was assessed by H&E, Masson and Sirius red staining. Cell viability was determined using Cell Counting Kit-8 (CCK-8) kits. Inflammation cytokine determination was conducted employing ELISA assays. Protein expression was detected by western blot, and immunohistochemical and immunofluorescence staining. Gene densities were analysed by quantitative real-time PCR assays. Co-immunoprecipitation analysis validated the interactions of nuclear factor erythroid 2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1).
resultsHDAC3 levels were increased in the serum and kidney tissues of patients with SLE and LN, and the LN group posted the highest level. HDAC3 knockdown ameliorated RIF, oxidative stress, inflammation and ferroptosis in kidney tissues of MRL/lpr mice. Moreover, HDAC3 inhibition repressed the inflammatory and oxidative reactions, fibrosis and ferroptosis in LN-serum-induced HK-2 cells. Further, HDAC3 knockdown could inhibit the Keap1-Nrf2 interaction to trigger Nrf2 activation.
conclusionHDAC3 inhibition relieved RIF, oxidative stress, inflammation and ferroptosis by upregulating Nrf2 in the mice and cell models of LN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.